Compare STRIDES PHARMA SCIENCE with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs STERLING BIOTECH - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE STERLING BIOTECH STRIDES PHARMA SCIENCE/
STERLING BIOTECH
 
P/E (TTM) x 42.0 -0.4 - View Chart
P/BV x 2.0 0.0 13,752.3% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 STRIDES PHARMA SCIENCE   STERLING BIOTECH
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
STERLING BIOTECH
Dec-13
STRIDES PHARMA SCIENCE/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,14711 10,923.8%   
Low Rs6423 18,882.4%   
Sales per share (Unadj.) Rs317.226.8 1,183.5%  
Earnings per share (Unadj.) Rs7.8-15.0 -52.4%  
Cash flow per share (Unadj.) Rs25.1-5.5 -458.7%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs274.354.9 499.7%  
Shares outstanding (eoy) m89.50267.87 33.4%   
Bonus / Rights / Conversions ESOP--  
Price / Sales ratio x2.80.3 1,087.5%   
Avg P/E ratio x114.0-0.5 -24,539.2%  
P/CF ratio (eoy) x35.7-1.3 -2,806.0%  
Price / Book Value ratio x3.30.1 2,575.6%  
Dividend payout %25.50-   
Avg Mkt Cap Rs m80,0581,862 4,300.3%   
No. of employees `0002.51.4 185.2%   
Total wages/salary Rs m4,341547 793.8%   
Avg. sales/employee Rs Th11,325.85,303.3 213.6%   
Avg. wages/employee Rs Th1,731.4403.8 428.7%   
Avg. net profit/employee Rs Th280.1-2,959.0 -9.5%   
INCOME DATA
Net Sales Rs m28,3947,181 395.4%  
Other income Rs m94143 2,208.0%   
Total revenues Rs m29,3347,223 406.1%   
Gross profit Rs m3,965947 418.8%  
Depreciation Rs m1,5402,543 60.6%   
Interest Rs m1,9624,377 44.8%   
Profit before tax Rs m1,403-5,931 -23.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m97-1,924 -5.1%   
Profit after tax Rs m702-4,007 -17.5%  
Gross profit margin %14.013.2 105.9%  
Effective tax rate %6.932.4 21.4%   
Net profit margin %2.5-55.8 -4.4%  
BALANCE SHEET DATA
Current assets Rs m24,83614,335 173.3%   
Current liabilities Rs m18,99349,809 38.1%   
Net working cap to sales %20.6-494.0 -4.2%  
Current ratio x1.30.3 454.4%  
Inventory Days Days71403 17.6%  
Debtors Days Days113171 66.5%  
Net fixed assets Rs m34,28955,432 61.9%   
Share capital Rs m895268 334.1%   
"Free" reserves Rs m23,65113,935 169.7%   
Net worth Rs m24,54614,701 167.0%   
Long term debt Rs m15,5139,478 163.7%   
Total assets Rs m65,43773,988 88.4%  
Interest coverage x1.7-0.4 -483.2%   
Debt to equity ratio x0.60.6 98.0%  
Sales to assets ratio x0.40.1 447.1%   
Return on assets %4.10.5 812.9%  
Return on equity %2.9-27.3 -10.5%  
Return on capital %6.9-6.4 -107.3%  
Exports to sales %025.9 0.0%   
Imports to sales %00.2 0.0%   
Exports (fob) Rs mNA1,860 0.0%   
Imports (cif) Rs mNA12 0.0%   
Fx inflow Rs m15,6971,860 844.0%   
Fx outflow Rs m73525 2,954.6%   
Net fx Rs m14,9621,835 815.4%   
CASH FLOW
From Operations Rs m1,8711,719 108.8%  
From Investments Rs m5,826-3,148 -185.1%  
From Financial Activity Rs m-10,1571,426 -712.3%  
Net Cashflow Rs m-2,615-3 76,908.5%  

Share Holding

Indian Promoters % 27.7 33.9 81.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 0.0 -  
FIIs % 8.6 9.9 86.9%  
ADR/GDR % 0.0 16.9 -  
Free float % 25.9 39.3 65.9%  
Shareholders   56,241 21,482 261.8%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   ALKEM LABORATORIES  FRESENIUS KABI ONCO.  TTK HEALTHCARE  TORRENT PHARMA  DISHMAN PHARMA  

Compare STRIDES PHARMA SCIENCE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Zooms 650 Points, Reclaims 50,000 Mark; Bajaj Finance & IndusInd Bank Top Gainers(09:30 am)

Asian share markets rose in early trade today, shrugging off worries about an increase in regional coronavirus infections and a subdued session on Wall Street.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY21); Net Profit Down 46.4% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 621 m (down 46.4% YoY). Sales on the other hand came in at Rs 8 bn (up 13.6% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY21); Net Profit Up 184.5% (Quarterly Result Update)

Aug 20, 2020 | Updated on Aug 20, 2020

For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

Is Intraday Trading For You?(Fast Profits Daily)

May 13, 2021

Do you think you have what it takes to be an intraday trader? Find out in this video.

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


May 18, 2021 12:48 PM

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE - TORRENT PHARMA COMPARISON

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS